1. Monte Rosa Therapeutics will host a webcast on December 16, 2025. 2. The focus will be interim results of MRT-2359 for prostate cancer. 3. MRT-2359 targets heavily pretreated metastatic castration-resistant prostate cancer patients. 4. Monte Rosa develops advanced Molecular Glue Degrader medicines for serious diseases. 5. Their pipeline includes first-in-class MGDs in oncology and autoimmune diseases.
FAQ
Why Bullish?
The upcoming webcast showcases significant clinical results, which may boost investor confidence. Historical examples show similar announcements often lead to stock price increases.
How important is it?
The event directly relates to clinical advancements, affecting investor perception and stock performance. Positive results could validate their innovative approach and inspire market interest.
Why Short Term?
The webcast's immediate impact on GLUE may lead to volatility pre and post-event. Previous biotech conferences influenced short-term stock movements significantly.
Monte Rosa Therapeutics to Present Updated Results from MRT-2359 Phase 1/2 Study
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company focused on developing innovative molecular glue degrader (MGD) medicines, has announced an upcoming live conference call and webcast. This event is scheduled for Tuesday, December 16, 2025, at 8:00 a.m. ET, and will showcase interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD MRT-2359, which is being tested in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).
Event Details and Access
The webcast presentation will be available in the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Interested participants can register for the conference call through the provided link. Additionally, an archived version of the webcast will be accessible for 30 days after the presentation, allowing stakeholders to review the findings at their convenience.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is at the forefront of biotechnology, specializing in developing highly selective molecular glue degrader (MGD) medicines. These innovative therapies aim to provide new treatment options for patients battling serious diseases, including cancer. MGDs are small molecule protein degraders that hold the potential to treat conditions unresponsive to other therapeutics, including various other degraders.
The company utilizes its proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine, which leverages AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics. This technology enables the rational design of MGDs with unprecedented selectivity.
Monte Rosa boasts an extensive pipeline of first-in-class and only-in-class MGDs, targeting a range of conditions such as autoimmune and inflammatory diseases and oncology. Currently, the company has three programs in clinical trials and is engaged in collaborations with leading pharmaceutical companies across immunology, oncology, and neurology.
Contact Information
- Investors: Andrew Funderburk, afunderburk@monterosatx.com
- Media: Cory Tromblee, Scient PR, media@monterosatx.com